References

• 1. Gibson W, Wagg A. Incontinence in the elderly, “normal” ageing, or unaddressed pathology? Nat Rev Urol. 2017;14(7):440-448. google scholar
• 2. Trowbridge ER, Wei JT, Fenner DE, Ashton-Miller JA, Delancey JOL. Effects of aging on lower urinary tract and pelvic floor function in nulliparous women. Obstet Gynecol. 2007;109(3):715-720. google scholar
• 3. Betschart C, Scheiner D, Maake C, et al. Histomorphological analysis of the urogenital diaphragm in elderly women: a cadaver study. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(11):1477-1481. google scholar
• 4. Siroky MB. The aging bladder. Rev Urol. 2004;6 Suppl 1:S3-7. google scholar
• 5. Kim JW, Kim SJ, Park JM, Na YG, Kim KH. Past, Present, and Future in the Study of Neural Control of the Lower Urinary Tract. Int Neurourol J. 2020;24(3):191-199. google scholar
• 6. Bultitude MF. Campbell-Walsh Urology Tenth Edition. Published online 2012. google scholar
• 7. Tong YC. Diagnosis and treatment of geriatric urinary incontinence. Incont Pelvic Floor Dysfunct. 2009;3(3):69-72. google scholar
• 8. Pfisterer MHD, Griffiths DJ, Schaefer W, Resnick NM. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc. 2006;54(3):405-412. google scholar
• 9. Chutka DS, Fleming KC, Evans MP, Evans JM, Andrews KL. Urinary incontinence in the elderly population. Mayo Clin Proc. 1996;71(1):93-101. google scholar
• 10. Griebling TL. Urinary incontinence in the elderly. Clin Geriatr Med. 2009;25(3):445-457. google scholar
• 11. Jeong SJ, Kim HJ, Lee YJ, et al. Prevalence and Clinical Features of Detrusor Underactivity among El-derly with Lower Urinary Tract Symptoms: A Comparison between Men and Women. Korean J Urol. 2012;53(5):342-348. google scholar
• 12. Naughton MJ, Wyman JF. Quality of life in geriatric patients with lower urinary tract dysfunction. Am J Med Sci. 1997;314(4):219-227. google scholar
• 13. Grimby A, Milsom I, Molander U, Wiklund I, Ekelund P. The influence of urinary incontinence on the quality of life of elderly women. Age Ageing. 1993;22(2):82-89. google scholar
• 14. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580-590. google scholar
• 15. Fernandez WG. NEW FRONTIERS IN GERIATRICS RESEARCH: AN AGENDA FOR SURGICAL AND RELATED MEDICAL SPECIALTIES.: Edited by David H. Solomon, Joseph LoCicero, and Ronnie Ann Rosenthal. New York, NY: American Geriatrics Society, 2004, 444 pages (softcover). Acad Emerg Med. 2006;13(4):475. google scholar
• 16. Lawhorne LW, Ouslander JG, Parmelee PA, Resnick B, Calabrese B. Urinary incontinence: a neglected geriatric syndrome in nursing facilities. J Am Med Dir Assoc. 2008;9(1):29-35. google scholar
• 17. Johnson TM, Kincade JE, Bernard SL, Busby-Whitehead J, Hertz-Picciotto I, DeFriese GH. The association of urinary incontinence with poor self-rated health. J Am Geriatr Soc. 1998;46(6):693-699. google scholar
• 18. Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc. 2000;48(4):413-416. google scholar
• 19. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1314; discussion 1314-1315. google scholar
• 20. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015-1033. google scholar
• 21. Yoshida M. Perspectives on overactive bladder in the elderly population. World J Urol. 2009;27(6):729-737. google scholar
• 22. Chancellor MB, Bartolone SN, Lamb LE, Ward E, Zwaans BMM, Diokno A. Underactive Bladder; Review of Progress and Impact From the International CURE-UAB Initiative. Int Neurourol J. 2020;24(1):3-11. google scholar
• 23. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy imp-lications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780-791. google scholar
• 24. Cho KJ, Kim JC. Management of Urinary Incontinence With Underactive Bladder: A Review. Int Neurourol J. 2020;24(2):111-117. google scholar
• 25. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487-1492. google scholar
• 26. Berardelli M, De Rango F, Morelli M, et al. Urinary incontinence in the elderly and in the oldest old: cor-relation with frailty and mortality. Rejuvenation Res. 2013;16(3):206-211. google scholar
• 27. Chong E, Chan M, Lim WS, Ding YY. Frailty Predicts Incident Urinary Incontinence Among Hospitalized Older Adults-A 1-Year Prospective Cohort Study. J Am Med Dir Assoc. 2018;19(5):422-427. google scholar
• 28. Veronese N, Soysal P, Stubbs B, et al. Association between urinary incontinence and frailty: a systematic review and meta-analysis. Eur Geriatr Med. 2018;9(5):571-578. google scholar
• 29. Jang IY, Lee CK, Jung HW, et al. Urologic symptoms and burden of frailty and geriatric conditions in older men: the Aging Study of PyeongChang Rural Area. Clin Interv Aging. 2018;13:297-304. google scholar
• 30. Bauer SR, Scherzer R, Suskind AM, et al. Co-Occurrence of Lower Urinary Tract Symptoms and Frailty among Community-Dwelling Older Men. J Am Geriatr Soc. 2020;68(12):2805-2813. google scholar
• 31. Park HJ, Park CH, Chang Y, Ryu S. Sitting time, physical activity and the risk of lower urinary tract symp-toms: a cohort study. BJU Int. 2018;122(2):293-299. google scholar
• 32. Chu CM, Khanijow KD, Schmitz KH, Newman DK, Arya LA, Harvie HS. Physical Activity Patterns and Sedentary Behavior in Older Women With Urinary Incontinence: an Accelerometer-based Study. Female Pelvic Med Reconstr Surg. 2019;25(4):318-322. google scholar
• 33. Suhr R, Lahmann NA. Urinary incontinence in home care: a representative multicenter study on prevalence, severity, impact on quality of life, and risk factors. Aging Clin Exp Res. 2018;30(6):589-594. google scholar
• 34. Rait G, Fletcher A, Smeeth L, et al. Prevalence of cognitive impairment: results from the MRC trial of assessment and management of older people in the community. Age Ageing. 2005;34(3):242-248. google scholar
• 35. Byles J, Millar CJ, Sibbritt DW, Chiarelli P. Living with urinary incontinence: a longitudinal study of older women. Age Ageing. 2009;38(3):333-338; discussion 251. google scholar
• 36. Lee SH, Cho ST, Na HR, Ko SB, Park MH. Urinary incontinence in patients with Alzheimer’s disease: relations-hip between symptom status and urodynamic diagnoses. Int J Urol Off J Jpn Urol Assoc. 2014;21(7):683-687. google scholar
• 37. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol Off J Jpn Urol Assoc. 2008;15(9):778-788. google scholar
• 38. Schmader K, Ritchie CS, Supiano MA, et al. Hazzard’s Geriatric Medicine and Gerontology. McGraw Hill; 2022. https://search.ebscohost.com/login.aspx?direct=true&AuthType=sso&db=cat09109a&AN=mer.oai.edge.umsystem.folio.ebsco.com.fs00001083.37322932.a199.57b7.8bed.646c6344a359&site=eds-live&s-cope=site&custid=s8436643 google scholar
• 39. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002;187(1):116-126. google scholar
• 40. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. google scholar
• 41. Herzog AR, Fultz NH. Prevalence and incidence of urinary incontinence in community-dwelling populati-ons. J Am Geriatr Soc. 1990;38(3):273-281. google scholar
• 42. Diokno AC, Brock BM, Brown MB, Herzog AR. Prevalence of urinary incontinence and other urological symptoms in the noninstitutionalized elderly. J Urol. 1986;136(5):1022-1025. google scholar
• 43. Resnick NM. Geriatric incontinence and voiding dysfunction. Campbell-Walsh Urol. Published online 2007:2305-2321. google scholar
• 44. Diokno AC, Lajiness MJ, Griebling TL. Urinary incontinence: evaluation and diagnosis. In: Geriatric Uro-logy. Springer; 2014:127-140. google scholar
• 45. Greer JA, Arya LA, Smith AL. Urinary incontinence: diagnosis and treatment in the elderly. Curr Transl Geriatr Exp Gerontol Rep. 2013;2(2):66-75. google scholar
• 46. Resnick NM, Marcantonio ER. How should clinical care of the aged differ? Lancet Lond Engl. 1997;350(9085):1157-1158. google scholar
• 47. Nambiar AK, Arlandis S, B0 K, et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022;82(1):49-59. google scholar
• 48. Jung HB, Kim HJ, Cho ST. A current perspective on geriatric lower urinary tract dysfunction. Korean J Urol. 2015;56(4):266-275. google scholar
• 49. Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4):S83. google scholar
• 50. Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008;72(2):318-321. google scholar
• 51. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-479. google scholar
• 52. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. The Prostate. 1990;17(3):241-246. google scholar
• 53. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20 Suppl 3:S11-18. doi:10.1038/ijir.2008.55 google scholar
• 54. Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099-1109. google scholar
• 55. Novara G, Galfano A, Gardi M, Ficarra V, Boccon-Gibod L, Artibani W. Critical review of guidelines for BPH diagnosis and treatment strategy. Eur Urol Suppl. 2006;5(4):418-429. google scholar
• 56. Bosch R, Abrams P, Cotterill N, et al. Lower Urinary Tract Symptoms in Men (Male LUTS): Etiology, Patient Assessment and Predicting Outcome from Therapy. Male Lower Urinary Tract Symptoms (LUTS), An International Consultation on Male LUTS. Published online 2013. google scholar
• 57. De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus. 2017;3(4-5):352-363. google scholar
• 58. Barry MJ, Fowler FJ, O’Leary MP, et al. The American Urological Association symptom index for be-nign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1557; discussion 1564. google scholar
• 59. Weissfeld JL, Fagerstrom RM, O’Brien B, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):390S-399S. google scholar
• 60. Roehrborn CG, Bartsch G, Kirby R, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology. 2001;58(5):642-650. google scholar
• 61. Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J, International Consultation on New Develop-ments in Prostate Cancer and Prostate Diseases. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2013;189(1 Suppl):S93-S101. google scholar
• 62. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999;54(4):662-669. google scholar
• 63. Gerber GS, Goldfischer ER, Karrison TG, Bales GT. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 1997;49(5):697-702. google scholar
• 64. Hong SK, Lee ST, Jeong SJ, et al. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2010;105(10):1424-1428. google scholar
• 65. Rule AD, Jacobson DJ, McGree ME, Girman CJ, Lieber MM, Jacobsen SJ. Longitudinal changes in post-vo-id residual and voided volume among community dwelling men. J Urol. 2005;174(4 Pt 1):1317-1321; discussion 1321-1322; author reply 1322. google scholar
• 66. Sullivan MP, Yalla SV. Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J Urol. 1996;155(6):1995-2000. google scholar
• 67. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int. 2006;97 Suppl 2:12-15; discussion 21-22. google scholar
• 68. Oelke M, Höfner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol. 2007;52(3):827-834. google scholar
• 69. J0rgensen JB, Jensen KM, Mogensen P. Age-related variation in urinary flow variables and flow curve patterns in elderly males. Br J Urol. 1992;69(3):265-271. google scholar
• 70. Kranse R, van Mastrigt R. Causes for variability in repeated pressure-flow measurements. Urology. 2003;61(5):930-934; discussion 934-935. google scholar
• 71. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram: I. Development. J Urol. 1979;122(5):665-668. google scholar
• 72. Koch WF, Ezz el Din K, de Wildt MJ, Debruyne FM, de la Rosette JJ. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol. 1996;155(1):186-189. google scholar
• 73. Grossfeld GD, Coakley FV. Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am. 2000;38(1):31-47. google scholar
• 74. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet Lond Engl. 2003;361(9366):1359-1367. google scholar
• 75. Wilkinson AG, Wild SR. Is pre-operative imaging of the urinary tract worthwhile in the assessment of prostatism? Br J Urol. 1992;70(1):53-57. google scholar
• 76. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54(2):419-426. google scholar
• 77. Oh MM, Choi H, Park MG, et al. Is there a correlation between the presence of idiopathic detrusor overac-tivity and the degree of bladder outlet obstruction? Urology. 2011;77(1):167-170. google scholar
• 78. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dys-function in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 2004;93(6):745-750. google scholar
• 79. Drake MJ, Lewis AL, Young GJ, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospi-tals. Eur Urol. 2020;78(5):701-710. google scholar
• 80. Arnolds M, Oelke M. Positioning invasive versus noninvasive urodynamics in the assessment of bladder outlet obstruction. Curr Opin Urol. 2009;19(1):55-62. google scholar
• 81. Manieri C, Carter SS, Romano G, Trucchi A, Valenti M, Tubaro A. The diagnosis of bladder outlet obstru-ction in men by ultrasound measurement of bladder wall thickness. J Urol. 1998;159(3):761-765. google scholar
• 82. Ball AJ, Feneley RC, Abrams PH. The natural history of untreated “prostatism.” Br J Urol. 1981;53(6):613-616. google scholar
• 83. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56(5 Suppl 1):3-6. google scholar
• 84. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmaco-logic intervention. Prostate Suppl. 1990;3:1-7. google scholar
• 85. Netto NR, de Lima ML, Netto MR, D’Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology. 1999;53(2):314-316. google scholar
• 86. Brown CT, Yap T, Cromwell DA, et al. Self management for men with lower urinary tract symptoms: ran-domised controlled trial. BMJ. 2007;334(7583):25. google scholar
• 87. Yap TL, Brown C, Cromwell DA, van der Meulen J, Emberton M. The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int. 2009;104(8):1104-1108. google scholar
• 88. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147 Suppl 2:S88-119. google scholar
• 89. Roehrborn CG. Three months’ treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis. 2006;9(2):121-125. google scholar
• 90. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179(2):616-621; discussion 621. google scholar
• 91. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the Com-bAT study. Eur Urol. 2010;57(1):123-131. google scholar
• 92. Karavitakis M, Kyriazis I, Omar MI, et al. Management of Urinary Retention in Patients with Benign Pros-tatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol. 2019;75(5):788-798. google scholar
• 93. Djavan B, Fong YK, Harik M, et al. Longitudinal study of men with mild symptoms of bladder outlet obst-ruction treated with watchful waiting for four years. Urology. 2004;64(6):1144-1148. google scholar
• 94. Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1(6):332-335. google scholar
• 95. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab. 1996;81(2):814-819. google scholar
• 96. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17-25. google scholar
• 97. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. google scholar
• 98. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology. 1995;46(5):631-637. google scholar
• 99. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119-126. google scholar
• 100. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533-539. d google scholar
• 101. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology. 1998;51(5):677-686. google scholar
• 102. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557-563. google scholar
• 103. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hy-perplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ Can Med Assoc J J Assoc Medicale Can. 1996;155(9):1251-1259. google scholar
• 104. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434-441. google scholar
• 105. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and AL-F-ONE. BJU Int. 2008;101 Suppl 3:17-21. google scholar
• 106. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2001;21(5-6):243-248. google scholar
• 107. Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A. 2000;97(17):9579-9584. d google scholar
• 108. Goldfischer ER, Sand PK, Thomas H, Peters-Gee J. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2015;34(1):37-43. google scholar
• 109. Baldwin CM, Keating GM. Transdermal oxybutynin. Drugs. 2009;69(3):327-337. google scholar
• 110. Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008;72(5):1061-1067; discussion 1067. google scholar
• 111. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174(6):2273-2275. discussion 2275-2276. google scholar
• 112. Yokoyama T, Uematsu K, Watanabe T, et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol. 2009;43(4):307-314. google scholar
• 113. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 Pt 1):999-1004; discussion 1004. google scholar
• 114. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651-658. google scholar
• 115. Gacci M, Sebastianelli A, Salvi M, et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015;16(9):60. d google scholar
• 116. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169(6):2253-2256. google scholar
• 117. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009;56(3):534-541. google scholar
• 118. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009;182(6):2825-2830. google scholar
• 119. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94(6):817-820. google scholar
• 120. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174(4 Pt 1):1334-1338. google scholar
• 121. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combi-nation with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83(9):1002-1010. google scholar
• 122. Yang Y, Zhao X feng, Li H zhong, et al. Efficacy and safety of combined therapy with terazosin and tolteradi-ne for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl). 2007;120(5):370-374. google scholar
• 123. van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003-1012. google scholar